Neurocrine Stock Falls On Unusually High Volume (NBIX)

NEW YORK ( TheStreet) -- Neurocrine Biosciences (Nasdaq: NBIX) is trading at unusually high volume Thursday with 1.3 million shares changing hands. It is currently at 4.6 times its average daily volume and trading down 47 cents (-5.4%) at $8.17 as of 10:10 a.m. ET.

Neurocrine has a market cap of $475.8 million and is part of the health care sector and drugs industry. Shares are up 0.4% year to date as of the close of trading on Wednesday.

Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company has a P/E ratio of 12.4, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Neurocrine as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. You can view the full Neurocrine Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.

Interested in other stocks that are falling on unusually high volume? Get free SMS text alerts sent to you when the action happens by texting HVDOWN to 95370 or select from multiple alert options.
null

If you liked this article you might like

10 Sectors That Will Profit Big-Time From Oil's Crash

Biotech Movers: Inovio, Neurocrine, Alnylam

Week in Review: Wall Street Sees Red as Geopolitical Issues Dominate, Earnings Begin

U.S. Markets Close Lower as Wall Street Frets Over Global Turmoil

Wall Street Closes Lower Amid Continued Global Worries